Depomed chops staff in restructuring

Depomed is cutting a fourth of its workforce as it slashes costs following an ill-fated late-stage study of its lead therapy, Gabapentin GR, the extended release version of a drug used against postherpetic neuralgia. Researchers announced last July that the trial had failed. There's no word of exact casualties, but the company had slightly more than 100 workers at the end of last year. 

"This reduction was difficult because it affects so many of our loyal, talented and hardworking employees," said CEO Carl Pelzel. "However, it was necessary in order to conserve cash and align our workforce to our needs in light of the disappointing results of our Phase III study in postherpetic neuralgia. The reduction in force is in addition to other ongoing cost-cutting initiatives."

- see the release for more on the cuts

Related Articles:
Depomed shares tank as drug flunks key trial. Report
Depomed demands $105M from Esprit Pharma. Report
Depomed inks $50M licensing deal on Proquin. Report

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.